Antihypertensive Medications and Differences in Muscle Mass in Older Persons: The Health, Aging and Body Composition Study

Objectives: To evaluate whether older persons using angiotensin‐converting enzyme (ACE) inhibitors have a larger lower extremity muscle mass (LEMM) than users of other antihypertensive drugs.

[1]  J. M. Guralnik,et al.  Drug data coding and analysis in epidemiologic studies , 1994, European Journal of Epidemiology.

[2]  H. Toyooka,et al.  The dose-related efficacy of diltiazem for enhancing diaphragmatic fatigability in dogs. , 2002, Anesthesia and analgesia.

[3]  J. Williamson,et al.  Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study , 2002, The Lancet.

[4]  M. Friedman,et al.  Relationship of physical symptoms and physical functioning to depression in patients with heart failure. , 2001, Heart & lung : the journal of critical care.

[5]  D. Chemla,et al.  Angiotensin-converting enzyme inhibitor therapy improves respiratory muscle strength in patients with heart failure. , 2001, Chest.

[6]  J. Chrast,et al.  Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I. , 2001, Endocrinology.

[7]  M. Friedman,et al.  Relationship of physical symptoms and physical functioning to depression in patients with heart failure , 2001 .

[8]  M. Redfield,et al.  Diastolic heart failure in the community , 2000, Current cardiology reports.

[9]  A. Matsuki,et al.  Effects of angiotensin-converting enzyme inhibitors on glucose uptake. , 2000, Hypertension.

[10]  J. Lombard,et al.  Short-term angiotensin converting enzyme inhibition reduces basal tone and dilator reactivity in skeletal muscle arterioles. , 2000, American journal of hypertension.

[11]  M. Farber,et al.  Tissue wasting in patients with chronic obstructive pulmonary disease. , 2000, Neurologic clinics.

[12]  C. Gatsonis,et al.  Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. , 2000, Archives of internal medicine.

[13]  C. Gatsonis,et al.  Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology. , 2000, Archives of internal medicine.

[14]  H. Folgering,et al.  Verapamil causes decreased diaphragm endurance but no decrease of nocturnal O2 saturation in patients with chronic obstructive pulmonary disease , 2000, European Journal of Clinical Pharmacology.

[15]  M. Pahor,et al.  Undertreatment of hypertension in community-dwelling older adults: a drug-utilization study in Dicomano, Italy. , 1999, Journal of hypertension.

[16]  J. McMurray,et al.  Cardiac cachexia--lean and mean. , 1999, European Heart Journal.

[17]  L. Cohn,et al.  Impact of body mass index and albumin on morbidity and mortality after cardiac surgery. , 1999, The Journal of thoracic and cardiovascular surgery.

[18]  P. Ponikowski,et al.  The impact of cachexia on cardiorespiratory reflex control in chronic heart failure. , 1999, European heart journal.

[19]  R. Ferrari,et al.  The role of TNF in cardiovascular disease. , 1999, Pharmacological research.

[20]  P. Gardiner,et al.  Nifedipine does not impede clenbuterol-stimulated muscle hypertrophy. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[21]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[22]  Jimmy D Bell,et al.  Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training , 1999, The Lancet.

[23]  S. Heymsfield,et al.  Epidemiology of sarcopenia among the elderly in New Mexico. , 1998, American journal of epidemiology.

[24]  D. Beasley,et al.  Phorbol ester and interleukin-1 induce interleukin-6 gene expression in vascular smooth muscle cells via independent pathways. , 1997, Journal of cardiovascular pharmacology.

[25]  M. Weir.  Population characteristics and the modulation of the renin-angiotensin system in the treatment of hypertension , 1997, Journal of Human Hypertension.

[26]  J. Lexell.  Sarcopenia and physical performance in old age , 1997 .

[27]  J. Lexell,et al.  Sarcopenia and physical performance in old age: Overview , 1997, Muscle & nerve. Supplement.

[28]  E. Hadley,et al.  The significance of sarcopenia in old age. , 1995, The journals of gerontology. Series A, Biological sciences and medical sciences.

[29]  J. Lexell,et al.  Human aging, muscle mass, and fiber type composition. , 1995, The journals of gerontology. Series A, Biological sciences and medical sciences.

[30]  M. Brown,et al.  The relationship of strength to function in the older adult. , 1995, The journals of gerontology. Series A, Biological sciences and medical sciences.

[31]  W. Evans.  What is sarcopenia? , 1995, The journals of gerontology. Series A, Biological sciences and medical sciences.

[32]  N. Rothwell,et al.  Anabolic effects of clenbuterol on skeletal muscle are mediated by beta 2-adrenoceptor activation. , 1992, The American journal of physiology.

[33]  C. Berne,et al.  Effects of Antihypertensive Treatment on Insulin Sensitivity With Special Reference to ACE Inhibitors , 1991, Diabetes Care.

[34]  A. Hirschman,et al.  Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs. , 1991, The American journal of physiology.

[35]  K. J. Lutz,et al.  A cross-sectional study of muscle strength and mass in 45- to 78-yr-old men and women. , 1991, Journal of applied physiology.

[36]  P. Reeds,et al.  The effect of beta-agonists and antagonists on muscle growth and body composition of young rats (Rattus sp.). , 1988, Comparative biochemistry and physiology. C, Comparative pharmacology and toxicology.